公开(公告)号：US07078485B2

公开(公告)日：2006-07-18

申请号：US10313638

申请日：2002-12-05

Applicant: Yongzhang Luo ,  Bing Zhou ,  Zhuobing Zhang

Inventor： Yongzhang Luo ,  Bing Zhou ,  Zhuobing Zhang

IPC: C07K1/00 ,  A61K61/00 ,  C12P21/06

CPC classification number: C07K14/78 ,  A61K38/00 ,  C07K2319/21

Abstract: The invention relates to endostatin protein, in particular, to N-terminal modified recombinant human endostatin (rhEndostatin) proteins which have an additional metal chelating peptide sequence at the N-terminal, the preparation thereof, and methods of modifying the rhEndostatin to improve its stability in vivo and in vitro, and its biological activity. The invention further related to the resulting N-terminal modified rhEndostatin protein, a pharmaceutical composition containing the same, and use of said modified rhEndostatin or its pharmaceutical composition in treating the angiogenesis-related diseases, especially angiogenesis-dependent tumors.

Abstract translation: 本发明涉及内皮抑素蛋白，特别涉及在N-末端具有额外的金属螯合肽序列的N-末端修饰的重组人内皮抑素（rhEndostatin）蛋白及其制备方法，以及修饰rhEndostatin以改善其稳定性的方法 体内和体外，及其生物活性。 本发明进一步涉及所得N-末端修饰的rhEndostatin蛋白，含有该组合物的药物组合物，以及所述修饰的rhEndostatin或其药物组合物在治疗血管发生相关疾病尤其是血管生成依赖性肿瘤中的用途。

公开(公告)号：US07470667B2

公开(公告)日：2008-12-30

申请号：US11118109

申请日：2005-04-29

Applicant: Yongzhang Luo ,  Zhuobing Zhang ,  Qingxin Lei ,  Yan Sun ,  Jinwan Wang

Inventor： Yongzhang Luo ,  Zhuobing Zhang ,  Qingxin Lei ,  Yan Sun ,  Jinwan Wang

IPC: A61K38/00

CPC classification number: C07K14/78 ,  A61K38/00 ,  C07K2319/21

Abstract: The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as a chemotherapy agent, or a radiotherapy agent.

Abstract translation: 本发明提供使用治疗有效量的修饰的内皮抑素蛋白治疗受试者的血管发生相关疾病的方法。 特别地，所述方法包括使用修饰的内皮抑制素和已知的癌症治疗剂如化疗剂或放射治疗剂的组合来治疗受试者的血管生成相关疾病。

公开(公告)号：US20060058232A1

公开(公告)日：2006-03-16

申请号：US11118109

申请日：2005-04-29

Applicant: Yongzhang Luo ,  Zhuobing Zhang ,  Qingxin Lei

Inventor： Yongzhang Luo ,  Zhuobing Zhang ,  Qingxin Lei

IPC: A61K38/22 ,  A61K31/7072 ,  A61K31/337 ,  A61K33/24

CPC classification number: C07K14/78 ,  A61K38/00 ,  C07K2319/21

Abstract: The present invention provides methods of treating an angiogenesis-related disease of a subject using a therapeutically effective amount of a modified endostatin protein. In particular, the methods encompass treating an angiogenesis-related disease of a subject using a combination of the modified endostatin, and a known cancer therapy agent such as a chemotherapy agent, or a radiotherapy agent.

Abstract translation: 本发明提供使用治疗有效量的修饰的内皮抑素蛋白治疗受试者的血管发生相关疾病的方法。 特别地，所述方法包括使用修饰的内皮抑制素和已知的癌症治疗剂如化疗剂或放射治疗剂的组合来治疗受试者的血管生成相关疾病。